# Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate

> **NCT01692652** · NA · COMPLETED · sponsor: **Yonsei University** · enrollment: 98 (actual)

## Conditions studied

- Moderate and Severe Meibomiang Gland Dysfunction (Stage 3 or Stage 4 Meibomiang Gland Dysfunction)

## Interventions

- **DRUG:** topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage
- **OTHER:** warm compress only group

## Key facts

- **NCT ID:** NCT01692652
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2014-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01692652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01692652, "Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01692652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*